233.4 is a legacy non-billable code used to specify a medical diagnosis of carcinoma in situ of prostate. This code was replaced on September 30, 2015 by its ICD-10 equivalent. The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data.
Other bursitis, not elsewhere classified, unspecified site M71. 50 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM M71. 50 became effective on October 1, 2021.
Prostate cancer is assigned to ICD-9-CM diagnosis code 185. Carcinoma in situ of the prostate is classified to code 233.4, and a benign neoplasm of the prostate goes to code 222.2.
Acquired absence of other genital organ(s) The 2022 edition of ICD-10-CM Z90. 79 became effective on October 1, 2021. This is the American ICD-10-CM version of Z90.
Coding/Billing for Prostate Cancer Screening Report HCPCS Level II code G0102 Prostate cancer screening; digital rectal examination or G0103 Prostate cancer screening; prostate specific antigen test (PSA), total, as appropriate, with ICD-10-CM diagnosis code Z12.
5: Special screening examination for neoplasm of prostate.
46: Personal history of malignant neoplasm of prostate.
Listen to pronunciation. (PROS-tuh-TEK-toh-mee) Surgery to remove part or all of the prostate and some of the tissue around it, including the seminal vesicles (a gland that helps make semen).
55866A. Robotic-assisted surgery is considered medically necessary for laparoscopic prostatectomy using the CPT code 55866.
The GEMs are the raw material from which providers, health information vendors and payers can derive specific applied mappings to meet their needs.
233.4 is a legacy non-billable code used to specify a medical diagnosis of carcinoma in situ of prostate. This code was replaced on September 30, 2015 by its ICD-10 equivalent.